One of the very few development and manufacturing partners with the capacity and technical expertise across multiple cell types at both clinical and commercial scale. Catalent has the leadership position in the biotech industry, gene therapy offering, and delivers comprehensive solutions for innovators bringing new treatment options to patients. With over 85 years of experience, Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. We became a publicly traded company (NYSE: CTLT) in 2014 and have grown to become a vibrant community of more than 11,000 employees who support over 7000 products for over 1000 customers all around the world. At Catalent, we share a common goal: to put Read more